BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients-Reference-Cited by-同舟云学术

BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients

Published:2012-04 Issue:2 Volume:92 Page:259-265
ISSN:0014-4800
Container-title:Experimental and Molecular Pathology
language:en
Short-container-title:Experimental and Molecular Pathology

Author:

Wongboonma Wanwisa,Thongnoppakhun Wanna,Auewarakul Chirayu U.

Publisher

Elsevier BV

Subject

Clinical Biochemistry,Molecular Biology,Pathology and Forensic Medicine

Reference49 articles.

1. The M351T BCR-ABL kinase mutation is uncommon in Asian patients with imatinib-resistant chronic myeloid leukemia: possible relationship with imatinib plasma levels;Ang,2008

2. Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia;Apperley;The Lancet Oncology,2007

3. Natural history of Southeast Asian chronic myeloid leukemia patients with different BCR-ABL gene variants;Auewarakul;Acta Haematologica,2006

4. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet;Baccarani;Journal of Clinical Oncology,2009

5. Hematology: nilotinib and dasatinib—new ‘magic bullets’ for CML?;Breccia;Nature Reviews. Clinical Oncology,2010

Cited by 17 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Asciminib antagonizes transplantable BCR::ABL1-positive lymphoid blast crisis in vivo by targeting malignant stem cells;Leukemia;2024-06-21

2. Ponatinib and STAT5 Inhibitor Pimozide Combined Synergistic Treatment Applications Potentially Overcome Drug Resistance via Regulating the Cytokine Expressional Network in Chronic Myeloid Leukemia Cells;Journal of Interferon & Cytokine Research;2024-04-01

3. Disease Response Assessment Modalities in Chronic Myeloid Leukemia: Past, Present, and Future;Indian Journal of Medical and Paediatric Oncology;2023-11-27

4. FDA Approval Summary: Revised Indication and Dosing Regimen for Ponatinib Based on the Results of the OPTIC Trial;The Oncologist;2022-02-01

5. Ultra-deep sequencing mutation analysis of the BCR/ABL1 kinase domain in newly diagnosed chronic myeloid leukemia patients;Leukemia Research;2021-12